Trial Profile
A phase 1 dose escalation study of the safety and pharmacokinetics of the KIT inhibitor XL820 administered orally daily to subjects with solid tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs XL 820 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Exelixis
- 17 Aug 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jun 2008 Status changed from recruiting to in progress according to ClinicalTrials.gov
- 12 Dec 2006 Status change